Welcome to our dedicated page for Merck & news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & stock.
Merck & Co., Inc. reports news across a global pharmaceutical business known as MSD outside the United States and Canada. Company updates center on human health products for areas such as oncology, cardiometabolic disease and infections; vaccines including Gardasil; and Merck Animal Health medicines, devices and customer-support systems.
Recurring developments include FDA approvals, clinical and regulatory disclosures, research publications, pipeline additions, business development transactions, material agreements, capital-structure updates, governance matters, and operating and financial results. Recent themes include the approved HIV-1 regimen IDVYNSO, investigational programs such as enlicitide decanoate and TERN-701, technology partnerships for research, manufacturing and commercial functions, and animal health digital engagement initiatives.
Merck (NYSE: MRK) will hold a first-quarter 2026 sales and earnings conference call at 9:00 a.m. ET on Thursday, April 30 for institutional investors and analysts. A live audio webcast will be available to the public.
A replay, the sales and earnings news release, supplemental financial disclosures and presentation slides will be posted at www.merck.com. Participants may join by dialing (800) 369-3351 (U.S./Canada) or (517) 308-9448 with access code 9818590.
Merck (NYSE: MRK) announced Phase 3 CORALreef AddOn results showing investigational oral PCSK9 inhibitor enlicitide decanoate reduced LDL-C by 64.6% at eight weeks versus baseline when added to statins and delivered significantly greater LDL-C reductions versus bempedoic acid, ezetimibe, and their combination.
Enlicitide improved goal attainment and key secondary lipids (ApoB, non‑HDL‑C, Lp(a)) with a safety profile consistent with prior CORALreef trials; FDA assigned a Commissioner’s National Priority Voucher in December 2025.
Merck (NYSE: MRK) reported positive Phase 2 CADENCE results for WINREVAIR (sotatercept-csrk) in adults with CpcPH-HFpEF, meeting the primary endpoint with a significant PVR reduction at week 24 (0.3 mg/kg: -1.02 WU, p=0.004; 0.7 mg/kg: -0.75 WU, p=0.024). Multiple hemodynamic, biomarker and clinical trends support advancing to a registrational Phase 3 program.
Merck (NYSE: MRK) agreed to acquire Terns Pharmaceuticals for $53.00 per share, valuing Terns at approximately $6.7 billion (about $5.7 billion net of acquired cash) with an expected close in Q2 2026.
The deal adds TERN-701, an oral allosteric BCR::ABL1 TKI in Phase 1/2 for certain CML patients with prior TKI exposure; TERN-701 has FDA Orphan Drug Designation (March 2024) and showed encouraging molecular responses by week 24. Merck expects a ~$5.8 billion charge (≈$2.35/share) in Q2 and full-year 2026 results; the transaction is subject to customary closing conditions and regulatory clearance.
Merck (NYSE: MRK) announced FDA approval (Mar 18, 2026) expanding the BRAVECTO® QUANTUM label to include Asian longhorned tick (H. longicornis) and Gulf Coast tick (A. maculatum) for 12 months after a single, veterinarian‑administered injection.
The product remains indicated for fleas and multiple other tick species (12 months for several species; 8 months for lone star tick) and is available exclusively through licensed veterinarians.
Merck (NYSE: MRK) will present new clinical and real-world data at the EUROGIN HPV Congress (March 18-21, 2026) in Vienna demonstrating long-term effectiveness of its HPV vaccines. Data show GARDASIL 9 effectiveness for at least 14 years after three doses and GARDASIL effectiveness up to 18 years after three doses against HPV16/18-related high-grade cervical disease.
The company will also present findings on certain HPV-related oropharyngeal cancers and trends in adult- and juvenile-onset recurrent respiratory papillomatosis from studies in the U.S., Denmark, Sweden, and the U.K.
Merck (NYSE: MRK) will present new cardio-pulmonary clinical data at ACC.26 (March 28-30, 2026) including two late-breaking presentations: positive Phase 3 CORALreef AddOn results for oral PCSK9 inhibitor enlicitide and positive Phase 2 CADENCE results for WINREVAIR™ (sotatercept-csrk) in CpcPH-HFpEF.
Presentations detail enlicitide efficacy/safety versus ezetimibe and bempedoic acid in statin-treated hypercholesterolemia and sotatercept outcomes in combined post-/pre-capillary pulmonary hypertension with HFpEF.
Merck (NYSE: MRK) reported Phase 3 LITESPARK-022 results: adjuvant KEYTRUDA + WELIREG reduced risk of recurrence or death by 28% (HR=0.72; p=0.0003) versus KEYTRUDA alone at median 28.4 months follow-up. Estimated 24-month DFS: 80.7% vs 73.7%. Grade ≥3 TEAEs occurred in 52.1% vs 30.2%. The FDA accepted supplemental applications with a PDUFA date of June 19, 2026.
Merck (NYSE: MRK) and Eisai reported Phase 3 LITESPARK-011 results showing WELIREG (belzutifan) plus LENVIMA (lenvatinib) reduced risk of progression or death by 30% versus cabozantinib (HR=0.70; p=0.00007).
Median PFS was 14.8 months vs 10.7 months; median OS trended higher at 34.9 months vs 27.6 months. FDA accepted two sNDAs with a PDUFA date of October 4, 2026.
Merck (NYSE: MRK) reported final Phase 3 KEYNOTE-B96 results showing KEYTRUDA (pembrolizumab) plus paclitaxel ± bevacizumab significantly improved overall survival (OS) versus paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer regardless of PD-L1. Median OS was 17.7 vs 14.0 months (HR=0.82; p=0.0115).
The regimen met primary PFS and key secondary OS endpoints; FDA approved the PD-L1 (CPS ≥1) indication and the CHMP issued a positive opinion.